Ibrutinib for Chronic Lymphocytic Leukemia with TP53 Alterations

被引：99
|
作者：
Ahn, Inhye E. [1 ]
Tian, Xin [1 ]
Wiestner, Adrian [1 ]
机构：
[1] NHLBI, Bldg 10, Bethesda, MD 20892 USA
来源：
NEW ENGLAND JOURNAL OF MEDICINE | 2020年 / 383卷 / 05期
关键词：
CLL;
D O I：
10.1056/NEJMc2005943
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Patients with chronic lymphocytic leukemia with chromosome 17 abnormalities have a worse prognosis than those without such alterations. In this phase 2 study, patients who received continuous ibrutinib had a durable response that continued after 6.5 years in some patients.
引用
收藏
页码：498 / 500
页数：3
相关论文
共 50 条
  • [21] Clinical impact of TP53 disruption in chronic lymphocytic leukemia patients treated with ibrutinib: a campus CLL study
    Riccardo Bomben
    Francesca Maria Rossi
    Filippo Vit
    Tamara Bittolo
    Antonella Zucchetto
    Robel Papotti
    Erika Tissino
    Federico Pozzo
    Massimo Degan
    Jerry Polesel
    Pietro Bulian
    Roberto Marasca
    Gianluigi Reda
    Luca Laurenti
    Jacopo Olivieri
    Annalisa Chiarenza
    Roberta Laureana
    Massimiliano Postorino
    Maria Ilaria Del Principe
    Antonio Cuneo
    Massimo Gentile
    Fortunato Morabito
    Gilberto Fronza
    Agostino Tafuri
    Francesco Zaja
    Robin Foà
    Francesco Di Raimondo
    Giovanni Del Poeta
    Valter Gattei
    Leukemia, 2023, 37 : 914 - 918
  • [22] Clinical impact of TP53 disruption in chronic lymphocytic leukemia patients treated with ibrutinib: a campus CLL study
    Bomben, Riccardo
    Rossi, Francesca Maria
    Vit, Filippo
    Bittolo, Tamara
    Zucchetto, Antonella
    Papotti, Robel
    Tissino, Erika
    Pozzo, Federico
    Degan, Massimo
    Polesel, Jerry
    Bulian, Pietro
    Marasca, Roberto
    Reda, Gianluigi
    Laurenti, Luca
    Olivieri, Jacopo
    Chiarenza, Annalisa
    Laureana, Roberta
    Postorino, Massimiliano
    Del Principe, Maria Ilaria
    Cuneo, Antonio
    Gentile, Massimo
    Morabito, Fortunato
    Fronza, Gilberto
    Tafuri, Agostino
    Zaja, Francesco
    Foa, Robin
    Di Raimondo, Francesco
    Del Poeta, Giovanni
    Gattei, Valter
    LEUKEMIA, 2023, 37 (04) : 914 - 918
  • [23] Clinical and Biological Impact of TP53 Alterations in Del(11q) Chronic Lymphocytic Leukemia
    Carretero, Claudia Perez
    Alamo, Miguel Quijada
    Hernandez-Sanchez, Maria
    Rodriguez, Ana E.
    Herrero, Ana B.
    Hernandez-Sanchez, Jesus M.
    Izquierdo, Marta Martin
    Gonzalez, Teresa
    Santos-Minguez, Sandra
    Miguel-Garcia, Cristina
    Rubio-Martinez, Araceli
    de Coca, Alfonso Garcia
    Davila, Julio
    Hernandez, Jose-Angel
    Benito, Rocio
    Ordonez, Jose Luis
    Hernandez-Rivas, Jesus Maria
    BLOOD, 2020, 136
  • [24] Selection of new TP53 mutations by therapy in chronic lymphocytic leukemia
    Trbusek, Martin
    Malcikova, Jitka
    Mayer, Jiri
    LEUKEMIA RESEARCH, 2011, 35 (07) : 981 - 982
  • [25] ERIC recommendations on TP53 mutation analysis in chronic lymphocytic leukemia
    S Pospisilova
    D Gonzalez
    J Malcikova
    M Trbusek
    D Rossi
    A P Kater
    F Cymbalista
    B Eichhorst
    M Hallek
    H Döhner
    P Hillmen
    M van Oers
    J Gribben
    P Ghia
    E Montserrat
    S Stilgenbauer
    T Zenz
    Leukemia, 2012, 26 : 1458 - 1461
  • [26] ERIC recommendations on TP53 mutation analysis in chronic lymphocytic leukemia
    Pospisilova, S.
    Gonzalez, D.
    Malcikova, J.
    Trbusek, M.
    Rossi, D.
    Kater, A. P.
    Cymbalista, F.
    Eichhorst, B.
    Hallek, M.
    Doehner, H.
    Hillmen, P.
    van Oers, M.
    Gribben, J.
    Ghia, P.
    Montserrat, E.
    Stilgenbauer, S.
    Zenz, T.
    LEUKEMIA, 2012, 26 (07) : 1458 - 1461
  • [27] TP53 Mutations are infrequent in newly diagnosed chronic lymphocytic leukemia
    Zainuddin, Norafiza
    Murray, Fiona
    Kanduri, Meena
    Gunnarsson, Rebeqa
    Smedby, Karin E.
    Enblad, Gunilla
    Jurlander, Jesper
    Juliusson, Gunnar
    Rosenquist, Richard
    LEUKEMIA RESEARCH, 2011, 35 (02) : 272 - 274
  • [28] Development of chronic myelogenous leukemia in a case of chronic lymphocytic leukemia with Tp53 gene deletion
    Gupta, A.
    Parihar, M.
    Yadav, A. K.
    Chakrapani, A.
    JOURNAL OF POSTGRADUATE MEDICINE, 2015, 61 (02) : 137 - +
  • [29] Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations
    Jain, Nitin
    Thompson, Philip
    Burger, Jan
    Ferrajoli, Alessandra
    Takahashi, Koichi
    Estrov, Zeev
    Borthakur, Gautam
    Bose, Prithviraj
    Kadia, Tapan
    Pemmaraju, Naveen
    Sasaki, Koji
    Konopleva, Marina
    Jabbour, Elias
    Garg, Naveen
    Wang, Xuemei
    Kanagal-Shamanna, Rashmi
    Patel, Keyur
    Wang, Wei
    Jorgensen, Jeffrey
    Wang, Sa
    Lopez, Wanda
    Ayala, Ana
    Plunkett, William
    Gandhi, Varsha
    Kantarjian, Hagop
    O'Brien, Susan
    Keating, Michael
    Wierda, William G.
    LEUKEMIA, 2021, 35 (12) : 3421 - 3429
  • [30] Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations
    Nitin Jain
    Philip Thompson
    Jan Burger
    Alessandra Ferrajoli
    Koichi Takahashi
    Zeev Estrov
    Gautam Borthakur
    Prithviraj Bose
    Tapan Kadia
    Naveen Pemmaraju
    Koji Sasaki
    Marina Konopleva
    Elias Jabbour
    Naveen Garg
    Xuemei Wang
    Rashmi Kanagal-Shamanna
    Keyur Patel
    Wei Wang
    Jeffrey Jorgensen
    Sa Wang
    Wanda Lopez
    Ana Ayala
    William Plunkett
    Varsha Gandhi
    Hagop Kantarjian
    Susan O’Brien
    Michael Keating
    William G. Wierda
    Leukemia, 2021, 35 : 3421 - 3429
12345